-+ 0.00%
-+ 0.00%
-+ 0.00%

Qiagen publishes 2025 annual report under IFRS

PUBT·04/30/2026 17:06:53
Listen to the news
Qiagen publishes 2025 annual report under IFRS
  • Qiagen published its 2025 annual report, outlining strategy built around five growth pillars led by QIAcuity digital PCR, QIAstat-Dx syndromic testing, QIAGEN Digital Insights, Sample technologies, QuantiFERON latent disease detection.
  • Strategy targets combined annual sales of about USD 2 billion from these pillars by 2028.
  • Report highlighted continued expansion of QIAstat-Dx installed base, with cumulative placements exceeding 5,200 instruments at end-2025.
  • Qiagen completed acquisitions of Parse Biosciences and Genoox during 2025 to broaden portfolio in molecular research and clinical testing.
  • Company employed about 5,700 people across more than 35 locations worldwide at end-2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief on April 30, 2026, and is solely responsible for the information contained therein.